Clinical trials: Research papers
- Critical Aspects of Clinical Trial Design for Novel Cell and Gene Therapies
Detailed evaluation of these discordant findings has highlighted several crucial issues such as patient selection criteria, details surrounding transplantation or gene therapy methodologies, as well as the study designs themselves that ought to be carefully considered in the planning phases of future clinical trials.
28 December 2011
- What motivates Parkinson's disease patients to enter clinical trials?
Conclusions: The main motivations of PD patients to participate in CTs were the benefit to the patient himself and to others. The major concern was safety. PD patients understood the informed consent, but more educational efforts must be made to explain the placebo effect.
01 November 2011
- Interpreting the results of Parkinson's disease clinical trials: time for a change
The authors argue that the failure of these clinical trials may be linked to end point-based statistical analyses that must make prior assumptions about the magnitude and the time course of wash-in and wash-out of drug effects
02 March 2011
- Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease
We compared 24-month outcomes for patients who had undergone bilateral stimulation of the globus pallidus interna (pallidal stimulation) or subthalamic nucleus (subthalamic stimulation).
03 June 2010
- Predictors of physician referral for patient recruitment to Alzheimer disease clinical trials
Proximity to a research center and availability of diagnostic clinical tools are strong predictors of clinical trial referral. Concern over risks to patients and lack of time are strong barriers.
01 November 2009
- Design of clinical trials of gene therapy in Parkinson disease
Some of the challenges of gene therapy clinical trial design are similar to those in studies of conventional pharmacological agents and include addressing the heterogeneity of the disease, the need for clinical and surrogate endpoints, and the issue of distinguishing symptomatic from neuroprotective effects.
01 January 2008
- Preclinical development of gene therapy for Parkinson's disease
While gene therapy has been mostly used so far for enhancing the expression of the target gene, the use of dominant negative or siRNA opens new possibilities. This, combined with the key feature of gene delivery that offers access to intracellular signalling pathways, is likely to further expand the number of proposed targets to be studied.
01 January 2008
- A randomized trial of deep-brain stimulation for Parkinson's disease
Neurostimulation of the subthalamic nucleus reduces levodopa-related motor complications in advanced Parkinson's disease. We compared this treatment plus medication with medical management.
31 August 2006
- The Alexander Technique: A Systematic Review of Controlled Clinical Trials
Alexander technique (AT), a process of psychophysical re-education, is being promoted for a range of medical conditions. This systematic review is aimed at critically evaluating the evidence for or against the effectiveness of AT.
01 October 2003
